苯并二氢吡喃衍生物的合成及其对骨和血管的初步生物活性

绝经后骨质疏松症的主要治疗手段是雌激素替代疗法 (ＨＲＴ) ,但长期用雌激素可引起子宫内膜和乳腺增生 ,增加发生子宫内膜癌和乳腺癌的危险性[1,2 ] 。异丙氧基异黄酮 (ｉｐｒｉｆｌａｖｏｎｅ)和 1998年初美国上市的选择性雌激素受体调节剂 (ＳＥＲＭｓ)雷洛昔芬 (ｒａｌｏｘｉｆｅｎｅ)可降低雌性激素样活性和致癌危险性 ,实现了雌激素的药理作用分离[3] 。异丙氧基异黄酮有很强的心血管保护作用 ,但其对绝经后骨质疏松症的防治效力不及雷洛昔芬[4 ,5] 。分析对比两种药物结构 :异丙氧基异黄酮较雷洛昔芬的结构简单 ,两者均含有苯并杂环 …

SYNTHESIS OF BENZODIHYDROPYRAN DERIVATIVES AND EVALUATION OF THEIR PRELIMINARY BIOLOGICAL ACTIVITIES ON BONE AND VASCULAR TISSUES

AIM: To screen optimal drugs against postmenopausal osteoporosis with cardiovascular protective activities. METHODS: A series of benzodihydropyran derivatives were designed and synthesized in view of comprehensive observations of raloxifene and ipriflavone. The antiosteoporosis activities of compounds a-e (10(-7) mol.L-1) on the proliferation of human osteoblast cell HOS TE85 were studied. The cardiovascular protective activities were evaluated by observing their effects on proliferation of human vascular endothelium cell ECV-304 and their protective effects on ECV-304 damaged by H2O2. RESULTS: Their structures were determined by spectrums. Compounds a, b and c (10(-7) mol.L-1) were shown to significantly help proliferation of HOS TE85. In addition, b, d and e (10(-8) mol.L-1) helped proliferation of ECV-304 significantly. Compounds b and c (10(-6) mol.L-1) showed strong protective activity on ECV-304 damaged by H2O2. Compounds b and c shifted the KCl dose-response curves to the right and decreased the maximal response. CONCLUSION: Compounds b and c showed some bone and vascular protective activities which benefit postmenopausal and cardiovascular diseases.